Safety and Immunogenicity of R21/Matrix-M1 Malaria Vaccine in West African Adults

Phase 2, randomised, single-blind trial of R21/Matrix-M in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Safety and Tolerability of Administration of R21/Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events at 7 days, Safety and Tolerability of R21/Matrix-M1 Assessed by the Occurrence of Unsolicited Adverse Events at 28 days and 2 more. Started Aug 2016; status: completed.